BioAdaptives Statistics
Total Valuation
BioAdaptives has a market cap or net worth of 746,062. The enterprise value is 1.05 million.
| Market Cap | 746,062 |
| Enterprise Value | 1.05M |
Important Dates
The next estimated earnings date is Monday, May 19, 2025.
| Earnings Date | May 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAdaptives has 9.05 million shares outstanding. The number of shares has increased by 14.80% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +14.80% |
| Shares Change (QoQ) | -8.70% |
| Owned by Insiders (%) | 2.93% |
| Owned by Institutions (%) | n/a |
| Float | 8.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,105.28 |
| PB Ratio | -0.47 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.33 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -579.05% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 49.87% |
| Revenue Per Employee | 675 |
| Profits Per Employee | -789,590 |
| Employee Count | 1 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 2.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.17% in the last 52 weeks. The beta is 0.73, so BioAdaptives's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -43.17% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 54.05 |
| Average Volume (20 Days) | 14,273 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioAdaptives had revenue of 675 and -789,590 in losses. Loss per share was -0.09.
| Revenue | 675 |
| Gross Profit | -80,921 |
| Operating Income | -783,406 |
| Pretax Income | -789,590 |
| Net Income | -789,590 |
| EBITDA | -782,921 |
| EBIT | -783,406 |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 39,564 in cash and 343,096 in debt, giving a net cash position of -303,532 or -0.03 per share.
| Cash & Cash Equivalents | 39,564 |
| Total Debt | 343,096 |
| Net Cash | -303,532 |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -1.57M |
| Book Value Per Share | -0.17 |
| Working Capital | -1.57M |
Cash Flow
| Operating Cash Flow | -306,242 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -116,060.15% |
| Pretax Margin | -116,976.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAdaptives does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.80% |
| Shareholder Yield | -14.80% |
| Earnings Yield | -105.83% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 23, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Jan 23, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |